Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported U.S. net sales of Linzess (linaclotide), its drug for irritable bowel syndrome with constipation and chronic idiopathic constipation, totaling $129.7 million for the fourth quarter and $454.8 million for full-year 2015, as reported by partner Allergan plc, of Dublin.